BDTX
Black Diamond Therapeutics, Inc.Company with tickers: BDTX
CIK
1701541
CUSIP
09203E105
Shares Outstanding
57,301,774
13F Activity (30d)
95 filings
95 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $11,259,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $7,003,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-11,259,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-9,036,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.16 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.16 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |